|
|
PD-L1和PD-1在前列腺癌中的表达及其临床意义
|
Abstract:
目的：探讨程序性死亡配体-1 (Programmed cell death-ligand 1, PD-L1)及程序性死亡受体-1 (Pro-grammed cell death-1, PD-1)在前列腺癌中的表达水平，及其与前列腺癌临床病理特征的相关性。方法：收集2014年2月至2018年10月在中山大学附属第五医院泌尿外科进行前列腺癌根治术，并经术后病理确诊的前列腺癌组织63例，另取癌旁2 cm外前列腺组织为正常对照组。用免疫组化法检测PD-L1和PD-1在前列腺癌及正常前列腺组织中的表达情况，并分析二者的表达与前列腺癌临床病理特征的关系。结果：63例前列腺癌组织中，PD-L1和PD-1的阳性表达均明显增高，而正常前列腺组织中未检测到PD-L1和PD-1表达(P = 0.000)；有淋巴结转移的前列腺癌组织中PD-L1和PD-1的表达明显高于无淋巴结转移组(PD-L1：75.00% vs 35.29%；PD-1：66.67% vs 33.33%，均P<0.05)；有骨结转移组PD-L1和PD-1的表达也高于无骨转移组(PD-L1：75.00% vs 38.18%；PD-1：75.00% vs 34.55%，均P < 0.05)。结论：PD-L1和PD-1在前列腺癌中的高表达与患者局部或远处转移密切相关，可能参与了前列腺癌的免疫逃逸。
Objective: To explore the expressions of programmed cell death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) in prostate cancer (PCa), and the correlation between PD-L1/PD-1 expressions with the clinical pathological features of PCa. Methods: Data of 63 patients who underwent radical prostatectomy in Department of Urology, the Fifth Affiliated Hospital of Sun Yat-sen University with PCa diagnosed by postoperative pathology from February 2014 to October 2018 were collected. We took normal prostate tissue 2 cm away from prostate cancer as a control group. The expressions of PD-L1 and PD-1 in PCa and normal prostate tissues were detected by immunohistochemistry, and the correlation between them with the clinical pathological features of PCa was analyzed. Results: The positive expressions of PD-L1 and PD-1 were significantly increased in 63 PCa tissues, while the expression of PD-L1 and PD-1 was not detected in normal prostate tissues (P = 0.000). The expressions of PD-L1 and PD-1 in lymph node metastasis group were significantly higher than those without lymph node metastasis (PD-L1: 75.00% vs 35.29%; PD-1: 66.67% vs 33.33%, P < 0.05). The expressions of PD-L1 and PD-1 in the bone metastasis group were also higher than that in the non-bone metastasis group (PD-L1: 75.00% vs 38.18%; PD-1: 75.00% vs 34.55%, P < 0.05). Conclusion: The high expressions of PD-L1 and PD-1 in PCa are closely related to local or distant metastasis of patients, and may be involved in immune escape of PCa.
| [1] | Modena, A., Ciccarese, C., Iacovelli, R., et al. (2016) Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncology Reviews, 10, 293. https://doi.org/10.4081/oncol.2016.293 |
| [2] | Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. and Riley, J.L. (2004) SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 Upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology, 173, 945-954. https://doi.org/10.4049/jimmunol.173.2.945 |
| [3] | Fife, B.T., Guleria, I., Gubbels Bupp, M., et al. (2006) Insulini-Induced Remission in New-Onset NOD Mice Is Maintained by the PD-1-PD-L1 Pathway. The Journal of Experimental Medicine, 203, 2737-2747. https://doi.org/10.1084/jem.20061577 |
| [4] | Tsushima, F., Yao, S., Shin, T., et al. (2007) Interaction between B7-H1 and PD-1 Determines Initiation and Reversal of T-Cell Anergy. Blood, 110, 180-185. https://doi.org/10.1182/blood-2006-11-060087 |
| [5] | Mountzios, G., Linardou, H. and Kosmidis, P. (2016) Immunotherapy in Non-Small Cell Lung Cancer: The Clinical impact of Immune Response and Targeting. Annals of Translational Medicine, 4, 268. https://doi.org/10.21037/atm.2016.06.24 |
| [6] | Albertsen, P. (2008) Predicting Survival for Men with Clinically Localized Prostate Cancer: What Do We Need in Contemporary Practice? Cancer, 112, 1-3. https://doi.org/10.1002/cncr.23107 |
| [7] | So, A., Gleave, M., Hurtado-Col, A. and Nelson, C. (2005) Mechanisms of the Development of Androgen Independence in Prostate Cancer. World Journal of Urology, 23, 1-9. https://doi.org/10.1007/s00345-004-0473-1 |
| [8] | Gajewski, T.F., Meng, Y. and Harlin, H. (2006) Immune Suppression in the Tumor Microenvironment. Journal of Immunotherapy, 29, 233-240. https://doi.org/10.1097/01.cji.0000199193.29048.56 |
| [9] | Dong, H., Strome, S.E., Salomao, D.R., et al. (2002) Tu-mor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nature Medicine, 8, 793-800. https://doi.org/10.1038/nm730 |
| [10] | Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331 |
| [11] | Wang, L., Ma, Q., Chen, X., et al. (2010) Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma. World Journal of Surgery, 34, 1059-1065. https://doi.org/10.1007/s00268-010-0448-x |
| [12] | Hasan, A., Ghebeh, H., Lehe, C., Ahmad, R. and Dermime, S. (2011) Thera-peutic Targeting of B7-H1 in Breast Cancer. Expert Opinion on Therapeutic Targets, 15, 1211-1225. https://doi.org/10.1517/14728222.2011.613826 |
| [13] | Karim, R., Jordanova, E.S., Piersma, S.J., et al. (2009) Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. Clinical Cancer Research, 15, 6341-6347. https://doi.org/10.1158/1078-0432.CCR-09-1652 |
| [14] | Hsu, M.C., Hsiao, J.R., Chang, K.C., et al. (2010) Increase of Programmed Death-1-Expressing Intratumoral CD8 T Cells Predicts a Poor Prognosis for Nasopharyngeal Carcinoma. Modern Pathology, 23, 1393-1403. https://doi.org/10.1038/modpathol.2010.130 |
| [15] | Loos, M., Langer, R., Schuster, T., et al. (2011) Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma. The Annals of Thoracic Surgery, 91, 1025-1031. https://doi.org/10.1016/j.athoracsur.2010.12.041 |
| [16] | Seo, S.K., Seo, H.M., Jeon, H.Y., et al. (2006) Co-Inhibitory Role of T Cell Associated B7-H1 and B7-DC in the T-Cell Immune Response. Immunology Letters, 102, 222-228. https://doi.org/10.1016/j.imlet.2005.09.007 |
| [17] | Hinrichs, C.S., Spolski, R., Paulos, C.M., et al. (2008) IL-2 and IL-24 Con-fer-Opposing Differentiation Programs to CD8+ T Cells for Adoptive Immunotherapy. Blood, 111, 5326-5333. https://doi.org/10.1182/blood-2007-09-113050 |
| [18] | 王永华. 共刺激分子B7-H1和Fasl在膀胱移行细胞癌免疫逃逸中的机制研究及临床意义[J]. 临床泌尿外科杂志, 2008, 23(9): 684-486. |
| [19] | Yang, S., Zhang, Q., Liu, S., et al. (2016) PD-1, PD-L1 and PD-L2 Expression in Mouse Prostate Cancer. American Journal of Clinical and Experimental Urology, 4, 1-8. |
| [20] | Graff, J.N., Alumkal, J.J., Drake, C.G., et al. (2016) Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer. Oncotarget, 7, 52810-52817. https://doi.org/10.18632/oncotarget.10547 |
